JP2016135771A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016135771A5 JP2016135771A5 JP2016001939A JP2016001939A JP2016135771A5 JP 2016135771 A5 JP2016135771 A5 JP 2016135771A5 JP 2016001939 A JP2016001939 A JP 2016001939A JP 2016001939 A JP2016001939 A JP 2016001939A JP 2016135771 A5 JP2016135771 A5 JP 2016135771A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- functional part
- antibody according
- sdr
- epidermidis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 241000894006 Bacteria Species 0.000 claims 3
- 241000191963 Staphylococcus epidermidis Species 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 230000000069 prophylactic effect Effects 0.000 claims 3
- 241000192125 Firmicutes Species 0.000 claims 2
- 206010041925 Staphylococcal infections Diseases 0.000 claims 2
- 241001147736 Staphylococcus capitis Species 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 241000191940 Staphylococcus Species 0.000 claims 1
- 241001147695 Staphylococcus caprae Species 0.000 claims 1
- 229940125644 antibody drug Drugs 0.000 claims 1
- 229940009098 aspartate Drugs 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22587809P | 2009-07-15 | 2009-07-15 | |
| US61/225,878 | 2009-07-15 | ||
| EP09165558.9 | 2009-07-15 | ||
| EP09165558 | 2009-07-15 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012520555A Division JP6192294B2 (ja) | 2009-07-15 | 2010-07-15 | グラム陽性菌特異的結合化合物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018072444A Division JP2018134089A (ja) | 2009-07-15 | 2018-04-04 | グラム陽性菌特異的結合化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016135771A JP2016135771A (ja) | 2016-07-28 |
| JP2016135771A5 true JP2016135771A5 (enExample) | 2016-12-22 |
Family
ID=41467048
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012520555A Expired - Fee Related JP6192294B2 (ja) | 2009-07-15 | 2010-07-15 | グラム陽性菌特異的結合化合物 |
| JP2016001939A Pending JP2016135771A (ja) | 2009-07-15 | 2016-01-07 | グラム陽性菌特異的結合化合物 |
| JP2018072444A Pending JP2018134089A (ja) | 2009-07-15 | 2018-04-04 | グラム陽性菌特異的結合化合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012520555A Expired - Fee Related JP6192294B2 (ja) | 2009-07-15 | 2010-07-15 | グラム陽性菌特異的結合化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018072444A Pending JP2018134089A (ja) | 2009-07-15 | 2018-04-04 | グラム陽性菌特異的結合化合物 |
Country Status (24)
| Country | Link |
|---|---|
| US (9) | US20110020323A1 (enExample) |
| EP (1) | EP2454284B1 (enExample) |
| JP (3) | JP6192294B2 (enExample) |
| KR (1) | KR101832201B1 (enExample) |
| CN (2) | CN102666583B (enExample) |
| AR (1) | AR077756A1 (enExample) |
| AU (2) | AU2010271582B2 (enExample) |
| BR (1) | BR112012000953A8 (enExample) |
| CA (1) | CA2768204A1 (enExample) |
| DK (1) | DK2454284T3 (enExample) |
| EA (1) | EA031447B1 (enExample) |
| ES (1) | ES2673323T3 (enExample) |
| HK (1) | HK1222418A1 (enExample) |
| HU (1) | HUE038277T2 (enExample) |
| IL (3) | IL217497A (enExample) |
| MX (1) | MX350234B (enExample) |
| NZ (2) | NZ616921A (enExample) |
| PL (1) | PL2454284T3 (enExample) |
| SG (2) | SG10201704269RA (enExample) |
| SI (1) | SI2454284T1 (enExample) |
| TR (1) | TR201809128T4 (enExample) |
| TW (2) | TWI502068B (enExample) |
| WO (1) | WO2011008092A2 (enExample) |
| ZA (2) | ZA201200363B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2540820T3 (pl) | 2005-12-09 | 2018-05-30 | Academisch Medisch Centrum Bij De Universiteit Van Amsterdam | Środki i sposoby wpływania na stabilność komórek wytwarzających przeciwciała |
| US9005974B2 (en) | 2005-12-09 | 2015-04-14 | Academish Medisch Centrum Bij De Universiteit Van Amsterdam | Means and methods for influencing the stability of cells |
| CN104231084B (zh) | 2009-05-13 | 2019-04-23 | 基酶有限公司 | 抗人cd52免疫球蛋白 |
| US20110020323A1 (en) | 2009-07-15 | 2011-01-27 | Tim Beaumont | Gram-positive bacteria specific binding compounds |
| JP5781508B2 (ja) | 2009-07-15 | 2015-09-24 | アイム・セラピューティクス・べー・フェー | 高親和性抗体を産生させるための手段および方法 |
| RU2585153C2 (ru) | 2010-12-02 | 2016-05-27 | Аимм Терапьютикс Б.В. | Средства и способы получения высокоаффинных антител |
| CN102559733A (zh) * | 2012-03-13 | 2012-07-11 | 黑龙江省科学院微生物研究所 | 导入clfA基因的乳酸乳球菌基因工程菌株的构建方法 |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| SG11201503232TA (en) * | 2012-11-06 | 2015-05-28 | Medimmune Llc | Antibodies to s. aureus surface determinants |
| US9809645B2 (en) | 2013-03-12 | 2017-11-07 | Zenyaku Kogyo Kabushikikaisha | Anti-Staphylococcus antibody, method for manufacturing same, and usage of same |
| AR095199A1 (es) * | 2013-03-15 | 2015-09-30 | Genzyme Corp | Anticuerpos anti-cd52 |
| US9803002B2 (en) | 2013-05-31 | 2017-10-31 | Genentench, Inc. | Anti-wall teichoic antibodies and conjugates |
| HUE050451T2 (hu) * | 2013-05-31 | 2020-12-28 | Genentech Inc | Anti-fal-teichonsav antitestek és konjugátumok |
| US9884126B2 (en) * | 2013-05-31 | 2018-02-06 | Genentech, Inc. | Anti-wall teichoic antibodies and conjugates |
| KR20160055269A (ko) | 2013-09-20 | 2016-05-17 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하기 위한 항-lag-3 항체 및 항-pd-1 항체의 조합물 |
| KR102775902B1 (ko) | 2013-12-17 | 2025-03-06 | 크링 바이오테라퓨틱스 비.브이. | 골수 증식성 또는 림프 증식성 질환에 대응하는 수단 및 방법 |
| EP3099709B1 (en) | 2014-01-31 | 2019-12-25 | AIMM Therapeutics B.V. | Means and methods for producing stable antibodies |
| JP6742314B2 (ja) * | 2014-12-03 | 2020-08-19 | ジェネンテック， インコーポレイテッド | 抗黄色ブドウ球菌抗体リファマイシン複合体及びその使用 |
| JP6751393B2 (ja) * | 2014-12-03 | 2020-09-02 | ジェネンテック， インコーポレイテッド | 抗ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ抗体リファマイシン抱合体及びその使用 |
| WO2016200926A1 (en) * | 2015-06-09 | 2016-12-15 | Techulon Inc. | Peptide nucleic acid molecules for treatment of gram positive bacterial infection |
| US10407510B2 (en) | 2015-10-30 | 2019-09-10 | Genentech, Inc. | Anti-factor D antibodies and conjugates |
| US10738338B2 (en) | 2016-10-18 | 2020-08-11 | The Research Foundation for the State University | Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate |
| HUE065242T2 (hu) | 2017-05-30 | 2024-05-28 | Bristol Myers Squibb Co | LAG-3-pozitív tumorok kezelése |
| CA3065304A1 (en) | 2017-05-30 | 2018-12-06 | Bristol-Myers Squibb Company | Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody |
| US11280788B2 (en) | 2019-01-31 | 2022-03-22 | Fresenius Medical Care Holdings, Inc. | Rapid diagnosis of peritonitis in peritoneal dialysis patients |
| KR102301987B1 (ko) * | 2019-11-14 | 2021-09-13 | 연세대학교 산학협력단 | 항체 선별 방법, 박테리아 오염 진단 방법 및 박테리아 오염 진단 키트 |
| US20250064921A1 (en) * | 2021-12-28 | 2025-02-27 | Cz Biohub Sf, Llc | Chemically modified bacterial peptidoglycan compositions and uses thereof |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0771351A1 (en) | 1994-06-07 | 1997-05-07 | The Rockefeller University | Surface protein of staphylococcus aureus |
| US6008341A (en) | 1994-08-22 | 1999-12-28 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | S. aureus fibrinogen binding protein gene |
| US6994855B1 (en) | 1994-08-22 | 2006-02-07 | The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | S. aureus fibrinogen binding protein gene |
| AU4714196A (en) * | 1995-01-30 | 1996-08-21 | Peter Truog | Antitumor and anticholesterol preparations containing a lipoteichoic acid from steptococcus |
| SE9602496D0 (sv) | 1996-06-20 | 1996-06-20 | Bengt Guss | Method and means for producing a fibrinogen binding protein and its use in biotechnology |
| US6610293B1 (en) | 1997-06-16 | 2003-08-26 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine | Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria |
| US6680195B1 (en) | 1997-11-26 | 2004-01-20 | Inhibitex, Inc. | Extracellular matrix-binding proteins from staphylococcus aureus |
| US6322788B1 (en) * | 1998-08-20 | 2001-11-27 | Stanley Arthur Kim | Anti-bacterial antibodies and methods of use |
| US6703025B1 (en) * | 1998-08-31 | 2004-03-09 | Inhibitex, Inc. | Multicomponent vaccines |
| IL141691A0 (en) | 1998-08-31 | 2002-03-10 | Trinity College Dublin | Polypeptides and polynucleotides from coagulase-negative staphylococci |
| US6692739B1 (en) * | 1998-08-31 | 2004-02-17 | Inhibitex, Inc. | Staphylococcal immunotherapeutics via donor selection and donor stimulation |
| CN1314450C (zh) | 1998-08-31 | 2007-05-09 | 英希比泰克斯公司 | 多组分疫苗 |
| CA2341177A1 (en) | 1998-08-31 | 2000-03-09 | Inhibitex, Inc. | Staphylococcal immunotherapeutics via donor selection and donor stimulation |
| US20030165527A1 (en) | 1998-12-22 | 2003-09-04 | Bengt Guss | Novel fibronectin-binding protein |
| US20040038327A1 (en) | 1999-08-31 | 2004-02-26 | Foster Timothy J. | Antibodies to polypeptides from coagulase-negative staphylococci |
| ES2372686T3 (es) * | 2001-01-26 | 2012-01-25 | Inhibitex, Inc. | Anitcuerpos monoclonales dirigidos contra la proteína clfa y modo de empleo en el tratamiento y prevención de infecciones. |
| GB0127983D0 (en) * | 2001-11-22 | 2002-01-16 | Neutec Pharma Plc | Treatment of micro-organism infection |
| CN1305905C (zh) | 2002-03-22 | 2007-03-21 | Aprogen株式会社 | 人源化抗体及其制备方法 |
| JP4686188B2 (ja) | 2002-09-13 | 2011-05-18 | ザ テキサス エイ アンド エム ユニバースティ システム | グラム陽性菌由来の表面固定化タンパク質を同定するためのバイオインフォマティクス法及びそれによって得られるタンパク質 |
| US20040151737A1 (en) | 2003-02-05 | 2004-08-05 | University Of Tennessee | Streptococcal serum opacity factors and fibronectin-binding proteins and peptides thereof for the treatment and detection of streptococcal infection |
| JP5102487B2 (ja) | 2003-03-07 | 2012-12-19 | ワイス・ホールディングズ・コーポレイション | 院内感染に対する免疫化のための多糖ブドウ球菌表面付着因子キャリアタンパク質接合体 |
| US20070026011A1 (en) | 2003-05-29 | 2007-02-01 | Inhibitex, Inc. | Sdr proteins from staphylococcus capitis and their use in preventing and treating infections |
| ES2579805T3 (es) * | 2004-09-23 | 2016-08-16 | Genentech, Inc. | Anticuerpos y conjugados modificados por ingeniería genética con cisteína |
| EP1850867A1 (en) * | 2005-01-10 | 2007-11-07 | Nabi Biopharmaceuticals | Method of treating staphylococcus aureus infection |
| US8475798B2 (en) | 2005-06-16 | 2013-07-02 | Inhibitex, Inc. | Monoclonal antibodies recognizing a coagulase-negative staphylococcal protein |
| AU2007221321B2 (en) | 2006-02-22 | 2012-06-28 | The Texas A & M University System | Antibodies recognizing a highly expressed putative antigen of CA-MRSA and methods of use |
| CA2881717C (en) * | 2006-06-06 | 2018-06-12 | Cecilia Anna Wilhelmina Geuijen | Human binding molecules having killing activity against staphylococci and uses thereof |
| JP5466635B2 (ja) * | 2007-03-30 | 2014-04-09 | メディミューン，エルエルシー | 脱アミド化プロフィールが低減した抗体 |
| CL2008001334A1 (es) | 2007-05-08 | 2008-09-22 | Genentech Inc | Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer. |
| CN101302504B (zh) * | 2007-05-11 | 2011-12-21 | 上海高科联合生物技术研发有限公司 | 一种抗体亲和层析纯化溶葡萄球菌酶的方法 |
| RU2557319C2 (ru) | 2007-07-16 | 2015-07-20 | Дженентек, Инк. | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ CD79b И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ПРИМЕНЕНИЯ |
| ES2381788T3 (es) | 2007-07-16 | 2012-05-31 | Genentech, Inc. | Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso |
| WO2009045434A2 (en) * | 2007-10-01 | 2009-04-09 | The Texas A & M University System | Inhibitors of staphylococcus aureus sdrd protein attachment to cells and uses therefor |
| US8937161B2 (en) | 2007-10-19 | 2015-01-20 | Genentech, Inc. | Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates |
| ES2960604T3 (es) | 2008-01-31 | 2024-03-05 | The Provost Fellows Found Scholars & The Other Members Of Board Of The College Of The Holy & Undiv T | Tratamiento de infecciones microbianas |
| HUE029869T2 (en) | 2008-01-31 | 2017-04-28 | Genentech Inc | Anti-cd79b antibodies and immunoconjugates and methods of use |
| US8280643B2 (en) | 2008-06-30 | 2012-10-02 | The Texas A & M University System | Crystal structure of Staphylococcus aureus clumping factor A in complex with fibrinogen derived peptide and uses thereof |
| HUE036372T2 (hu) | 2009-06-22 | 2018-07-30 | Wyeth Llc | Staphylococcus aureus antigének immunogén készítményei |
| US20110020323A1 (en) | 2009-07-15 | 2011-01-27 | Tim Beaumont | Gram-positive bacteria specific binding compounds |
| EP2453915B1 (en) | 2009-07-16 | 2017-04-19 | The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin | Treatment of infections |
-
2010
- 2010-07-15 US US12/837,358 patent/US20110020323A1/en not_active Abandoned
- 2010-07-15 TR TR2018/09128T patent/TR201809128T4/tr unknown
- 2010-07-15 EA EA201390967A patent/EA031447B1/ru not_active IP Right Cessation
- 2010-07-15 ES ES10734844.3T patent/ES2673323T3/es active Active
- 2010-07-15 CN CN201080041138.6A patent/CN102666583B/zh not_active Expired - Fee Related
- 2010-07-15 TW TW099123405A patent/TWI502068B/zh not_active IP Right Cessation
- 2010-07-15 BR BR112012000953A patent/BR112012000953A8/pt not_active Application Discontinuation
- 2010-07-15 EP EP10734844.3A patent/EP2454284B1/en not_active Not-in-force
- 2010-07-15 AR ARP100102587A patent/AR077756A1/es unknown
- 2010-07-15 TW TW104126578A patent/TW201610153A/zh unknown
- 2010-07-15 HU HUE10734844A patent/HUE038277T2/hu unknown
- 2010-07-15 NZ NZ616921A patent/NZ616921A/en not_active IP Right Cessation
- 2010-07-15 PL PL10734844T patent/PL2454284T3/pl unknown
- 2010-07-15 MX MX2014012186A patent/MX350234B/es unknown
- 2010-07-15 NZ NZ598063A patent/NZ598063A/en not_active IP Right Cessation
- 2010-07-15 WO PCT/NL2010/050456 patent/WO2011008092A2/en not_active Ceased
- 2010-07-15 SG SG10201704269RA patent/SG10201704269RA/en unknown
- 2010-07-15 KR KR1020127003839A patent/KR101832201B1/ko not_active Expired - Fee Related
- 2010-07-15 CA CA2768204A patent/CA2768204A1/en not_active Abandoned
- 2010-07-15 SI SI201031701T patent/SI2454284T1/en unknown
- 2010-07-15 DK DK10734844.3T patent/DK2454284T3/en active
- 2010-07-15 SG SG2012002622A patent/SG177653A1/en unknown
- 2010-07-15 CN CN201510639968.3A patent/CN105440133A/zh active Pending
- 2010-07-15 JP JP2012520555A patent/JP6192294B2/ja not_active Expired - Fee Related
- 2010-07-15 AU AU2010271582A patent/AU2010271582B2/en not_active Ceased
-
2011
- 2011-11-28 US US13/305,659 patent/US8617556B2/en not_active Expired - Fee Related
-
2012
- 2012-01-12 IL IL217497A patent/IL217497A/en not_active IP Right Cessation
- 2012-01-17 ZA ZA2012/00363A patent/ZA201200363B/en unknown
-
2013
- 2013-03-05 US US13/786,206 patent/US9399673B2/en not_active Expired - Fee Related
- 2013-03-05 US US13/786,215 patent/US9090677B2/en not_active Expired - Fee Related
- 2013-12-11 US US14/103,715 patent/US9266943B2/en not_active Expired - Fee Related
-
2014
- 2014-01-27 ZA ZA2014/00644A patent/ZA201400644B/en unknown
-
2015
- 2015-04-01 IL IL238074A patent/IL238074A/en not_active IP Right Cessation
- 2015-06-02 US US14/728,826 patent/US9458228B2/en not_active Expired - Fee Related
- 2015-10-22 IL IL242207A patent/IL242207A0/en unknown
- 2015-12-28 US US14/981,643 patent/US9688745B2/en not_active Expired - Fee Related
-
2016
- 2016-01-07 JP JP2016001939A patent/JP2016135771A/ja active Pending
- 2016-08-24 US US15/246,301 patent/US9927428B2/en not_active Expired - Fee Related
- 2016-09-05 HK HK16110533.5A patent/HK1222418A1/zh unknown
- 2016-10-27 AU AU2016250398A patent/AU2016250398B2/en not_active Ceased
-
2018
- 2018-02-20 US US15/900,589 patent/US20180292391A1/en not_active Abandoned
- 2018-04-04 JP JP2018072444A patent/JP2018134089A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016135771A5 (enExample) | ||
| Gao et al. | Quinolone derivatives and their activities against methicillin-resistant Staphylococcus aureus (MRSA) | |
| Assis et al. | New strategies for targeting and treatment of multi-drug resistant Staphylococcus aureus | |
| Vuong et al. | Investigational drugs to treat methicillin-resistant Staphylococcus aureus | |
| Saylor et al. | Monoclonal antibody-based therapies for microbial diseases | |
| Del Rio et al. | Patients at risk of complications of Staphylococcus aureus bloodstream infection | |
| Ohlsen et al. | Immunotherapeutic strategies to combat staphylococcal infections | |
| JP2021063090A5 (enExample) | ||
| Berry et al. | Antibodies in infectious diseases: polyclonals, monoclonals and niche biotechnology | |
| Projan et al. | Staphylococcal vaccines and immunotherapy: to dream the impossible dream? | |
| Munita et al. | Enterococcal endocarditis: can we win the war? | |
| JP2017519768A5 (enExample) | ||
| JP2012518624A5 (enExample) | ||
| SG10201811361XA (en) | Treatment of polybacterials infections | |
| SI2454284T1 (en) | Compounds that specifically bind to Gram-positive bacteria | |
| Varshney et al. | Humanized staphylococcal enterotoxin B (SEB)–specific monoclonal antibodies protect from SEB intoxication and Staphylococcus aureus infections alone or as adjunctive therapy with vancomycin | |
| BRPI1010948A2 (pt) | Composição compreendendo pelo menos trans- cinamaldeído e a respectiva utilização no tratamento das infecções bacterianas, mais particularmente no tratamento das doenças nosocomiais. | |
| Yagupsky | Antibiotic susceptibility of Kingella kingae isolates from children with skeletal system infections | |
| François et al. | Antibody-based therapy to combat Staphylococcus aureus infections | |
| Rezazadeh et al. | Antibiotic profile of methicillin-resistant Staphylococcus aureus with multiple-drug resistances isolated from nosocomial infections in Vali-Asr Hospital of Arak | |
| Ter Meulen | Monoclonal antibodies in infectious diseases: clinical pipeline in 2011 | |
| WO2017137954A3 (en) | Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease | |
| JP2024009968A5 (enExample) | ||
| Castanheira et al. | 690. Activity of a novel polymyxin analog, QPX9003, tested against resistant Gram-negative pathogens, including carbapenem-resistant Acinetobacter, Enterobacterales, and Pseudomonas | |
| JP2016510749A5 (enExample) |